Oyster Point Pharma, Inc, operating under the umbrella of Viatris, is a global healthcare company formed in 2020 through the merger of Mylan and Upjohn, a division of Pfizer. Viatris is dedicated to transforming healthcare by providing high-quality, trusted medicines to patients worldwide, regardless of their location or circumstances. The company emphasizes access to affordable healthcare, sustainable operations, and innovative solutions to enhance patient health. With a commitment to empowering individuals at every stage of life, Viatris leverages its extensive manufacturing and scientific expertise to ensure that quality medicines are available when and where they are needed. Viatris fosters an inclusive work environment and values diverse perspectives, aiming to make a significant impact on global health outcomes.